Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Blair William & Co. IL

Blair William & Co. IL lowered its stake in Illumina, Inc. (NASDAQ:ILMN) by 4.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 24,981 shares of the life sciences company’s stock after selling 1,149 shares during the quarter. Blair William & Co. IL’s holdings in Illumina were worth $2,608,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of ILMN. Bouvel Investment Partners LLC lifted its holdings in shares of Illumina by 1.3% in the 1st quarter. Bouvel Investment Partners LLC now owns 6,547 shares of the life sciences company’s stock worth $899,000 after acquiring an additional 84 shares during the last quarter. UMB Bank n.a. lifted its stake in Illumina by 7.0% during the second quarter. UMB Bank n.a. now owns 1,341 shares of the life sciences company’s stock worth $140,000 after purchasing an additional 88 shares in the last quarter. Gulf International Bank UK Ltd boosted its position in shares of Illumina by 0.7% during the first quarter. Gulf International Bank UK Ltd now owns 13,562 shares of the life sciences company’s stock worth $1,862,000 after buying an additional 98 shares during the period. GAMMA Investing LLC grew its stake in shares of Illumina by 4.9% in the first quarter. GAMMA Investing LLC now owns 2,258 shares of the life sciences company’s stock valued at $310,000 after buying an additional 105 shares in the last quarter. Finally, Texas Permanent School Fund Corp raised its holdings in shares of Illumina by 0.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 32,818 shares of the life sciences company’s stock valued at $4,507,000 after buying an additional 114 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Stock Down 2.4 %

Shares of NASDAQ ILMN opened at $131.20 on Monday. The stock has a market cap of $20.90 billion, a PE ratio of -16.10 and a beta of 1.15. Illumina, Inc. has a 52-week low of $89.00 and a 52-week high of $148.19. The business has a 50-day moving average price of $125.25 and a 200 day moving average price of $120.47. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 1.04.

Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $0.24. Illumina had a negative net margin of 68.73% and a positive return on equity of 3.08%. The business had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.09 billion. During the same period last year, the firm posted $0.32 earnings per share. The company’s revenue for the quarter was down 5.4% compared to the same quarter last year. Equities research analysts forecast that Illumina, Inc. will post 3.62 earnings per share for the current year.

Wall Street Analyst Weigh In

ILMN has been the subject of several research reports. JPMorgan Chase & Co. dropped their target price on Illumina from $130.00 to $125.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $242.00 target price on shares of Illumina in a research note on Wednesday, August 14th. Robert W. Baird raised their price target on shares of Illumina from $119.00 to $124.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. TD Cowen raised Illumina from a “hold” rating to a “buy” rating and upped their price objective for the stock from $126.00 to $144.00 in a research report on Wednesday, August 14th. Finally, Barclays upgraded Illumina from an “underweight” rating to an “equal weight” rating and set a $125.00 target price for the company in a report on Wednesday, August 14th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $151.05.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.